Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Managing to Prevent Fracture: Guideline-based therapy Presented by: John A. Goldman, MD Chief of Rheumatology, Saint Joseph’s Hospital, Atlanta, GA 1 Content Provided By: Michael Maricic, MD, Catalina Pointe Rheumatology; Clinical Associate Professor of Medicine, University of Arizona & Robin K. Dore, MD, Clinical Professor of Medicine and Rheumatology, UCLA, Los Angeles, CA; Private Practice, Tustin, CA 2 Objectives Apply the National Osteoporosis Foundation’s guidelines for screening patients for osteoporosis Formulate evidence-based treatment plans for patients with osteoporosis or fracture according to WHO/NOF recommendations. 3 4 Annual incidence of common diseases Significance of Osteoporosis in Women 2,051,0001 2,000,000 297,000 hip 1,500,000 397,000 wrist 675,000 other sites 1,000,000 135,000 pelvic 500,000 370,0002 547,000 vertebral 0 Osteoporotic Fractures Heart Attack 425,0002 182,4603 Stroke Breast Cancer 1Annual fracture incidence in women all ages estimate new & recurrent MI ages 35+ 2Annual estimate new & recurrent stroke in women all ages 32008 new cases in situ & invasive breast cancer all ages 2Annual © 2008. National Osteoporosis Foundation. All rights reserved. www.nof.org 1 Burge, et al. JBMR. 2007. 465-75. American Heart Association. Heart Disease and Stroke Statistics – 2009 Update. 2009. 3 American Cancer Society. Surveillance Research. 2008. Use of WHO Fracture Risk Algorithm The WHO Fracture Risk Assessment Tool (FRAX®) was developed to calculate the absolute 10-yr probability of a Hip fracture and any Major Osteoporotic Fracture • Hip • Vertebra • Forearm • Humerus The algorithm takes into account femoral neck BMD and clinical risk factors for fracture Adapted from Kanis JA et al. Osteoporos Int. 2005;16:581-589. 6 FRAX Absolute Fracture Risk T-score alone does not provide a complete assessment of fracture risk Combination of clinical risk factors with BMD provides a better way of identifying patients for treatment 7 Risk Factor Data Sources 12 large prospective population-based cohorts: • CaMos, DOES, EPIDOS, EVOS/EPOS, Gothenburg I & II, Rochester, Hiroshima, Kuopio, OLEFY, Rotterdam, Sheffield 59,644 subjects with 252,000 person-years 5,321 fractures, including 1141 hip fractures Validated in 11 additional study cohorts not used in developing the original algorithm Kanis JA et al. WHO Technical Report. 2007. 8 Non-density Related Risk Factors Age Previous low trauma fracture Parental history of hip fracture Current cigarette smoking High alcohol intake (> 3 units/day) Rheumatoid arthritis Current or prior glucocorticoid use Adapted from Kanis JA et al. Osteoporos Int. 2005;16:581-589. 9 10 FRAX Calculation Tool http://www.shef.ac.uk/FRAX 11 WHO Absolute Risk Prediction Model 10-Year probability of experiencing an osteoporosis-related fracture Treatment intervention thresholds will vary by country Recommendations for treatment based on absolute fracture risk—not simply on Tscores 14 Case 1 The patient is a 65-year-old white female who presents for her first DXA scan She had her menopause at age 50 and never took hormone therapy She weighs 132 pounds and is 5’4” She currently smokes and her father broke his hip Her spine and femoral neck T-score today are both -1.8 15 Audience Response Question 16 When to Use FRAX™ for Making Treatment Decisions Postmenopausal women and men age 50 and older with osteopenia- who do not qualify for treatment based on other treatment indications • Have a fragility fracture or • T-score > -2.5 at the hip or spine 19 When Not to Use FRAX for Making Treatment Decisions Patients who already meet treatment indications (they have a fragility fracture or T-score ≤ -2.5 at the hip or spine) Patients with a normal T-score Patients already on treatment Premenopausal women and men under age 50 20 Limitations of FRAX BMD for femoral neck input only • Spine BMD is not taken into account “Dose effect” not taken into account (glucocorticoids, RA, smoking, alcohol) Many risk factors not considered • Fall risk • Rate of bone loss or turnover 21 NOF Guidelines for Pharmacologic Therapy in Postmenopausal Women and in Men >50 Initiation of pharmacologic therapy recommended in presence of any one of: Fracture A vertebral or hip fracture T-Score T-score ≤ –2.5 at femoral neck, total hip or spine FRAX® Assessment if T-score between -1.0 and -2.5 • 10-year probability of a major fracture ≥ 20% • 10-year probability of a hip fracture ≥ 3% National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2008. 22 2008 NOF Guide: Treatment Initiation Postmenopausal Women and Men ≥ 50 years Basic Care (suitable for all) Assess Risk Factors and BMD (if risk factors) T-score between -1.0 and -2.5 Hip or vertebral fractures or T-score ≤ -2.5 (spine, FN, or total hip) Other fractures > age 50 (excluding fingers, toes and face) 10-year probability of hip fractures > 3% or probability of all major fractures > 20% (FN or total T-score only) Secondary causes with high fracture risk* *Such as glucocorticoid use www.NOF.org 23 Old NOF Guidelines vs. New NOF Guidelines Case 55 year-old Caucasian woman (120 lbs, 5’-2”) with T-score = -2.1 80 year-old Caucasian woman (120 lbs, 5’-2”) with T-score = -1.1 Old Guide Treat (T-score < 2.0) New Guide Don’t Treat (10 year risk of major fracture 10%, hip 1.5%) Don’t Treat (T-score ≥ 1.5) Treat (10-year risk of major fracture 24%, hip 2.4%) 24 25 Therapy of Patients with Osteoporosis and at High Risk of Fracture Lifestyle modification Drug treatment 26 27 27 National Osteoporosis Foundation: March 2007 Recommendations Recommended Intake for Adults 50 Years and Older Calcium Vitamin D3 Previous (2003)1 March 2007 revision2 (mg/day) (IU/day) 1200 400–800 1200 800–1000 1. National Osteoporosis Foundation. Physician’s Guide to Prevention and Treatment of Osteoporosis. Available at: http://www.nof.org/physguide/index.asp. Accessed April 26, 2007. 2. National Osteoporosis Foundation. National Osteoporosis Foundation’s Updated Recommendations for Calcium and Vitamin D3 Intake. Available at: http://www.nof.org/prevention/calcium_and_VitaminD.htm. Accessed April 26, 2007. 28 What type of Calcium should we use? Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture Case-control study conducted using the GPRD in the UK Users of PPI therapy, H2 receptor antagonists and controls older than 50 years 13,556 hip fracture cases and 135,386 controls The adjusted odds ratio (AOR) for hip fracture associated with more than 1 year of PPI therapy was 1.44 (95% CI1.30-1.59) The strength of the association increased with increasing dose and duration of PPI therapy Yang Y, Lewis J, Epstein S. JAMA. 2006;296:2947-2953 29 Vitamin D Insufficiency (<30 ng/mL): Prevalence by Latitude n=259/532 (48.7%) 42 N n=342/642 (53.3%) 35 N n=198/362 (54.7%) P = NS for Test of Trend. Holick MF et al. JCEM 2005 30 Vitamin D 25-OH D levels should be measured in patients • At risk for osteoporosis • Being treated for osteoporosis • Those at risk for falls, especially the elderly 25-OH D level attained should be at least 30 ng/ml Many patients need more than 1000 units/day and higher intakes are safe It is the serum level of 25-OH D attained that is important, not the dose! 31 Higher 25(OH)D Levels Are Associated With Better Lower Extremity Function in Ambulatory Women Timed Sit-to-Stand Test 4,100 ambulatory adults — 8-ft walking speed test — Timed sit-to-stand test LOWESS = locally weighted regression plot. Reference range of 22.5–94.0 nmol/L (9.0–37.7 ng/mL). N = 4,100; P<0.001. 32 Sit-to-stand time, s included in NHANES III 60 to 90 years Functional measurements used to assess lower extremity function: LOWESS regression plot of lower extremity function vs vitamin D levels Reference range 15 14 0 8 16 24 32 40 48 Serum 25(OH)D, ng/mL Adapted with permission by the American Journal of Clinical Nutrition. © Am J Clin Nutr. American Society for Clinical Nutrition. 56 64 Agents for Postmenopausal Osteoporosis Documented Fracture Reduction Spine Nonvertebral Hip Antiresorptive Agents (Bisphosphonates) Alendronate X X X Ibandronate X - - Risedronate X X X Zoledronic acid X X X Calcitonin X - - Estrogen+progesterone X X (all fractures) X Raloxifene X - - X X - Antiresorptive Agents (Other) Anabolic Agent Teriparatide No head-to-head trials compare fracture outcomes 33 Reduction in Fracture Risk With Calcitonin The primary efficacy end point was the risk of new vertebral fractures in the salmon calcitonin nasal spray 200 IU group compared with placebo Placebo Calcitonin 100 IU Calcitonin 200 IU Calcitonin 400 IU 30 Percent with New Fractures (%) 1,255 postmenopausal women with established osteoporosis were randomly assigned to salmon calcitonin nasal spray (100, 200, or 400 IU) or placebo daily 26.0% 25 22.0% 20 22.0% * 18.0% 15 10 5 0 * P<0.05 versus placebo Chesnut CH III, et al. Am J Med. 2000;109:267-276. Vertebral Fractures 34 Reduction in Risk for Fractures With Estrogen Therapy and Estrogen-Progestogen Therapy Postmenopausal women aged 50-79 years Prior hysterectomy Percent with Any Osteoporotic Fractures (%) 0.17% Placebo) 0.17% 0.15% * * 0.11% 0.11% Vertebral * P<0.05 vs placebo ET Percent with Any Osteoporotic Fractures (%) Placebo No prior hysterectomy at baseline Hip EPT 0.15% * * 0.10% 0.09% Vertebral Hip ET, estrogen therapy; EPT, estrogen-progestogen therapy Women’s Health Initiative Investigators. JAMA. 2002;288:321-333. Women’s Health Initiative Investigators. JAMA. 2004;291:1701. 35 Risks and Benefits of Estrogen + Progestin * * * * * * * CHD = coronary heart disease VTE = venous thromboembolism Women’s Health Initiative Investigators. JAMA. 2002;288:321-333. * P<0.05 versus no treatment 36 Risks and Benefits of Estrogen * * * * * P<0.05 versus no treatment Women’s Health Initiative Investigators. JAMA. 2004;291:1701-1712. 37 Effect of HT on CHD: Timing of Initiation Years Since Menopause WHI-E+P Absolute Risk per 10,000 Women per Year of HT Use 0.88 P for trend=0.05 <10 -4 1.23 10-19 7 1.66 >20 30 WHI-E 0.48 -14 P for trend=0.15 <10 0.96 -1 10-19 1.12 7 >20 WHI-Combined 0.76 -6 P for trend=0.02 <10 1.10 4 10-19 1.28 16 >20 0 0.5 1.0 Rossouw JE, JAMA 2007;297:1465-1477. 1.5 2.0 2.5 Estrogen/Hormone Therapy Side Effects Hormone Therapy Estrogen Therapy Venous thrombosis Not Significant Heart Disease Not Significant Stroke Gallbladder Disease Breast Cancer Not Significant Dementia 2009. National Osteoporosis Foundation. www.nof.org 39 FDA Recommendations about ET/HT The FDA recommends the following: When prescribing medication to prevent osteoporosis, consider all nonestrogen preparations first When prescribing ET/HT, prescribe smallest dose for shortest time to achieve treatment goals Prescribe ET/HT products only when benefits are believed to outweigh risks for a specific patient US Food and Drug Administration. FDA News. January 8, 2003. 2009. National Osteoporosis Foundation. www.nof.org 40 Hormone/Estrogen Therapy It is important to consider all of the risks and benefits of HT/ET when prescribing to individual patients HT/ET are very effective agents for prevention of bone loss and fractures Risks differ according whether using HT versus ET, and the age of the patient No need to combine full dose HT with a bisphosphonate 41 Reduction in Risk for Vertebral Fractures With Raloxifene * Results for patients with no fractures at baseline Ettinger B, et al. JAMA. 1999;282:637-645. 5 4.5% Percent with New Vertebral Fractures (%)* The Multiple Outcomes of Raloxifene Evaluation (MORE) study enrolled 7,705 women aged 31-80 years who had been postmenopausal for ≥2 years and who met World Health Organization criteria for osteoporosis Participants were randomized to 60 or 120 mg/day raloxifene or placebo Primary end point: incident vertebral fracture Placebo Raloxifene (60 mg/day) Raloxifene (120 mg/day) 4 ** 3 ** 2.8% 2.3% 2 1 0 ** P<0.05 versus placebo 42 Risk-Benefit Considerations with Raloxifene The risks for both hip and vertebral fractures also increase with age4 The clinician may want to consider removing a patient from raloxifene therapy at about age 65 Increase in Fractures with Age in Women4 160,000 140,000 Number of Fractures Raloxifene is associated with both VTE and stroke and the risk for both events increases with age1-3 Hip Vertebral 120,000 100,000 80,000 60,000 40,000 20,000 0 50-64 65-74 75-84 ≥85 Age (years) Evista (raloxifene) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2007. Silverstein MD, et al. Arch Intern Med. 1998;158:585-593. American Heart Association. 2008. Available at: http://www.americanheart.org/presenter.jhtml?identifier=9217. Burge R, et al. J Bone Min Res. 2007;22:465-475. 43 Oral Bisphosphonates Alendronate- Weekly Risedronate- Weekly, monthly Ibandronate- Monthly 44 Reduction in Risk for Vertebral Fractures with Alendronate Black DM, et al. Lancet. 1996;348:1535-1541. 16 15.0% Placebo Alendronate 14 Percent with New Vertebral Fractures (%) 2,027 women aged 55-81 years with low femoral-neck BMD and at least one vertebral fracture at baseline were randomly assigned placebo (1,005) or alendronate (1,022) and followed up for 36 months The dose of alendronate (initially 5 mg/day) was increased to 10 mg /day at 24 months Lateral spine radiography was done at baseline and at 24 and 36 months Primary end point: new morphometric or clinical vertebral fractures 12 10 * 8.0% 8 6 5.0% * 4 2.3% 2 0 Morphometric Fractures Clinical Fractures * P<0.05 versus placebo 45 Reduction in Risk for Vertebral and Nonvertebral Fractures With Risedronate Randomly assigned to 3 years of risedronate (2.5 or 5 mg/day) or placebo 18 Percent with New Fractures (%) Randomized, double-blind placebo-controlled trial of 2,458 postmenopausal women <85 years old with ≥1 vertebral fracture at baseline 16.3% Placebo Risedronate 16 14 12 ** 11.3% 10 8 6 8.4% * 5.2% 4 2 Primary end point: incidence of new vertebral 0 fractures as detected by Vertebral Fractures radiography * P=0.02 versus placebo Nonvertebral Fractures ** P=0.003 versus placebo 46 Harris ST, et al. JAMA. 1999;282:1344-1352. Reduction in Risk for Vertebral Fractures with Ibandronate Percent with New Vertebral Fractures (%) 2,946 postmenopausal 12 women with osteoporosis were 10 randomized to placebo or oral ibandronate 8 administered daily (2.5 mg/day) or 6 intermittently (20 mg every other day for 4 12 doses every 3 months) 2 Primary end point: incidence of new 0 vertebral fractures after * P<0.05 versus placebo 3 years ** P=0.0006 versus placebo *** P=0.0001 versus placebo Placebo Daily Ibandronate Intermittent Ibandronate 9.6% *** 4.7% ** 4.9% 5.3% * 2.8% Morphometric Fractures Chesnut CH III, et al. J Bone Min Res. 2004;19:1241-1249. * 2.8% Clinical Fractures 47 Adherence With Oral Bisphosphonates Is Poor, Regardless of Dosing 100 Patients on Therapy (%) 90 Percentage of Patients on Therapy (defined as having at least 1 day of medication supply in the month) 80 70 60 54.6% 50 40 36.9% 30 Weekly Bisphosphonates (n=177,552) 20 Daily Bisphosphonates (n=33,767) P<0.001 vs daily therapy 10 Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct 2002 2003 A HIPAA-compliant, longitudinal patient database of prescriptions dispensed from ~25% of US retail pharmacies was used to assess discontinuation of bisphosphonates over a 12-month period in women aged ≥50 years.* * Primary usage in osteoporosis; however, data may include use in other indications. Ettinger M, et al. Arthritis Rheum. 2004;50(suppl):S513-S514. Abstract 1325. 48 Poor Compliance and Persistence Lead to Compromised Fracture Risk Reduction N = 11,249 Fracture Risk Hazard Ratio 1.0 16% Risk Reduction P < .001 0.8 0.6 0.4 0.2 0 Low Compliance High Compliance Siris et al, 20062 N = 35,537 14 24 Month Fracture Risk (%) Caro et al, 20041 12 12.6% 29% Risk Reduction P < .001 10 8 9.4% 6 4 2 0 1. Caro JJ, et al. Osteoporos Int. 2004;15:1003-1008. 2. Siris E et al. Mayo Clin Proc 2006;81:1013-1022 NonPersistent Persistent 49 I.V. Bisphosphonates: Potential Clinical Usage Assure compliance where there is evidence for non-compliance Assure absorption when in doubt clinically Oral bisphosphonate intolerance or contraindications • Dysphagia, severe GERD, Bed-ridden patients 50 I.V. Bisphosphonates Ibandronate- 3 mg Q 3 months • Treatment of postmenopausal OP Zoledronic acid- 5 mg once yearly • Treatment of postmenopausal OP • Treatment of men with low bone mass • Treatment of patients on glucocorticoids • Prevention of osteoporosis (5 mg every 2 years) 51 Reduction in Risk for Vertebral and Hip Fractures With Zoledronic Acid 12 Percent with New Fractures (%) 3,889 patients (mean age, 73 years) were randomly assigned to receive a single 15minute infusion of zoledronic acid (5 mg) and 3,876 were assigned to receive placebo at baseline, 12, and 24 months Patients were followed for 36 months Primary end points were: • New vertebral fractures (in patients not taking concomitant osteoporosis medications) • Hip fractures (in all patients) 10 8 6 4 ** 3.3% 2.5% 2 * 1.4% 0 * P=0.002 versus placebo ** P<0.001 versus placebo Black DM, et al. N Engl J Med. 2007;356:1809-1822. Placebo Zoledronic Acid 10.9% Vertebral Fractures Hip Fractures 52 Zoledronic acid – Adverse Reactions Incidence rate (%) The most common adverse events were post dose flu-like symptoms 53 Zoledronic Acid – Adverse Reactions Acute Renal Failure• 24 cases of ARF and 3 deaths reported in July FDA newsletter • Many of these patients should not have been candidates for ZA • Do not give if creatinine clearance < 35 mg/ml • Infuse over minimum of 15 minutes 54 Case 2 The patient is a 75-year-old diabetic, hypertensive white female with osteoporosis Her meds include glyburide, lisinopril, furosemide and ibuprofen prn for arthritis Her spine T-score is -2.4 and femoral neck T-score is -3.0 She cannot tolerate oral bisphosphonates due to GI discomfort Her creatinine clearance is 36 ml/min 55 Audience Response Question 56 Answer to Case 2 NO Although her creatinine clearance is 36 ml/min (above the FDA exclusionary limit of 35 ml/min), she has other risk factors for chronic renal disease which include chronic diabetes and hypertension Also she is taking a number of other meds which can influence renal function including ibuprofen, lisinopril, and furosemide She would be a significant risk of acute renal failure from IV zoledronic acid, and this agent should be avoided Teriparatide would be a preferred option 58 Osteonecrosis of the Jaw A confirmed case of bisphosphonate-associated ONJ was defined as an area of exposed bone in the maxillofacial region that did not heal within 8 weeks after identification by a health care provider In a patient who was receiving or had been exposed to a bisphosphonate Osteonecrosis of the Jaw A condition in which bone in the jaw becomes exposed, typically after a dental extraction or some other trauma and the wound that occurs fails to heal in the usual time frame. In patients receiving bisphosphonates for appropriate indications, the benefits far outweigh the risks. 2009. National Osteoporosis Foundation. www.nof.org 60 Osteonecrosis of the Jaw Low incidence, most often in cancer patients receiving high doses of IV bisphosphonates, but also rarely diagnosed in patients on oral bisphosphonates for nonmalignant conditions. In 2005 FDA required addition of statement on ONJ risk for all bisphosphonate products. 2009. National Osteoporosis Foundation. www.nof.org 61 ONJ Comparative Risks M. Lewiecki 2007 Kanis JA et al. Osteoporos Int. 2001;12:417-427. Pharmcoepidemiol Drug Saf. 2003;12:195-202. National Center for Health Statistics. JADA. 2006;137:1144-1150. Alendronate: Is Long Term Use Linked to Subtrochanteric Femoral Fractures? ABC News Good Morning America March 9, 2010 63 Radiograph Showing a Subtrochanteric Stress Fracture Associated with a Typical Cortical Stress Reaction Kwek E et al. N Engl J Med 2008;359:316-318 64 Atypical Fractures of Femoral Shaft Transverse fractures of the femoral shaft Bilateral in 2/3 of patients Delayed healing or non-healing common Prolonged use (> 5 years) of alendronate +/other anti-resorptive medications Severely suppressed bone turnover? 65 Atypical Fractures of Femoral Diaphysis Visekruna, J Clin Endocrinol Metab 2008;93:2948-2952 66 Subtrochanteric and Diaphyseal Femur Fractures in Patients Treated With Alendronate: Note the proportional increase in the risk of both typical and atypical fractures in the alendronate cohort Abrahamsen B., Eiken P., Eastell R. J Bone Miner Res. 2009 Jun;24(6):1095-102 69 Comparison of Number of Patients Who Would Need to Be Treated for 3 Years with Bisphosphonates to Prevent One Fracture and the Hypothetical Number Associated with an Increase of One Subtrochanteric or Diaphyseal Fracture Black D et al. N Engl J Med 2010;362:1761-1771 70 FDA Drug Safety Communication: Ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fractures March 10,2010 “At this point, the data that FDA has reviewed have not shown a clear connection between bisphosphonate use and a risk of atypical subtrochanteric femur fractures”. 71 FDA recommends that Patients should: Not stop taking medication unless told to do so by your healthcare professional. Talk to their healthcare professional if they develop new hip or thigh pain, or have any concerns with their medications. Report any side effects with bisphosphonates to FDA's MedWatch program FDA Drug Safety Communication: Ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fractures March 10,2010 72 FDA recommends that Healthcare Professionals should: Be aware of the possible risk of atypical subtrochanteric femur fractures in patients taking oral bisphosphonates. Continue to follow the recommendations on the drug label when prescribing oral bisphosphonates. Discuss with patients the known benefits and potential risks with using oral bisphosphonates. Report any adverse events with the use of oral bisphosphonates to FDA's MedWatch program FDA Drug Safety Communication: Ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fractures March 10,2010 73 Subtrochanteric Fractures Occur in patients never exposed to bisphosphonates Case control studies to date do not indicate an increase with bisphosphonate use In patients on bisphosphonates complaining of lower extremity “loading” pain, check x-ray and/or MRI 74 Bisphosphonate Holiday? 75 Bisphosphonate Holiday? FLEX Trial ALN/PLB (n = 437) ALN/ALN (n = 662) Fracture Incidence, % RR = 1.0 CI (0.8, 1.3) RR = 0.9 CI (0.6, 1.2) RR = 0.45 CI (0.2, 0.8) 5% 2% Clinical Vertebral RR = 1.0 CI (0.5, 2.1) 11% 10% Vertebral Morphometric 1. Black DM et al. JAMA. 2006;296:2927–2938. 19% 19% Nonvertebral 3% 3% Hip 76 Bisphosphonate Holiday? Warranted in those who never needed treatment in the first place Use FRAX if BMD before starting Rx if available Continue treatment in those who have had fractures and those whose T-scores are < -2.5 Not clear when to end holiday Arbitrary restart after 1-2 years? Follow BMD, markers? 77 Teriparatide or Parathyroid Hormone (1-34) (PTH) Classified as an anabolic agent that builds new bone Administered daily by subcutaneous injection Decreases risk of vertebral fractures and nonvertebral fractures after an average of 18 months of therapy Neer RM et al. N Engl J Med. 2011;344(19):1434-1441. 2009. National Osteoporosis Foundation. www.nof.org 78 Teriparatide Teriparatide (human parathyroid hormone (1-34), is the only currently approved anabolic agent for osteoporosis. It is indicated for the treatment of postmenopausal women with osteoporosis who are at high risk for fracture. These include those who (based on physician assessment)… • Have a history of osteoporotic fracture • Have multiple risk factors for fracture • Failed previous osteoporosis therapy • Are intolerant to previous osteoporosis therapy 79 Teriparatide Indications continued “High-risk” includes: Men/women with previous osteoporotic fracture(s) Men/women with multiple risk factors for fracture Men/women with extremely low BMD (-3.0 and below) Patients unresponsive or intolerant of other osteoporosis therapies US Food and Drug Administration. FDA Talk Paper. November 26, 2002. 2009. National Osteoporosis Foundation. www.nof.org 80 Patients (%) Effect of Teriparatide (PTH) on New Vertebral and Nonvertebral Fractures at 18 Months 65%* 53%* *P<.05 for all values with PTH. Neer RM et al. N Engl J Med. 2001;344:1434–1441. 81 Teriparatide: Contraindications Hypercalcemia Paget's disease of bone Growing children and young adults Pregnant or nursing women A history of bone cancer A history of cancer that has metastasized to the bones Radiation to the skeleton from any condition US food and drug administration. FDA talk papers. November 26, 2002 82 Denosumab June 1, 2010 Denosumab (Prolia – Amgen) – approved for treatment of postmenopausal women with osteoporosis at high risk for fracture 83 OPG / RANKL / RANK Receptor RANKL and OPG are secreted by osteoblasts and bone marrow stromal cells RANKL functions to promote osteoclast formation and activation and inhibit apoptosis Hormones Cytokines RANK Ligand RANK OPG Osteoblasts Osteoclast Precursor RANK Osteoclast Bone OPG functions as a decoy receptor to prevent RANKL signaling; ratio of RANKL to OPG dictates bone mass and structural properties Current extensive research is elucidating the role of OPG and RANKL in a wide variety of bone-related diseases 84 Denosumab (OPG mimetic) Denosumab is a fully human monoclonal antibody against the receptor activator of nuclear factor-kB ligand RANK Ligand (RANKL) IgG2 High affinity for RANK Ligand (Kd 3 x 10–12 M) Does not bind to TNFα, TNFß, TRAIL, or CD40L Bekker PJ, et al. J Bone Miner Res. 2004;19:1059-1066. Boyle WJ, et al. Nature. 2003;423:337-342. Monoclonal Antibody Model 85 Mechanism of Action for Denosumab Osteoclast Activation Osteoclast Formation, Function and Survival Inhibited Denosumab CFU-M OPG RANKL Pre-Fusion Osteoclast RANK Multinucleated Osteoclast Growth Factors Hormones Cytokines Mature Osteoclast Bone Adapted from Boyle WJ, et al. Nature. 2003;423:337-42. Original Article Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis Steven R. Cummings, M.D., Javier San Martin, M.D., Michael R. McClung, M.D., Ethel S. Siris, M.D., Richard Eastell, M.D., Ian R. Reid, M.D., Pierre Delmas, M.D., Ph.D., Holly B. Zoog, Ph.D., Matt Austin, M.S., Andrea Wang, M.A., Stepan Kutilek, M.D., Silvano Adami, M.D., Ph.D., Jose Zanchetta, M.D., Cesar Libanati, M.D., Suresh Siddhanti, Ph.D., Claus Christiansen, M.D., for the FREEDOM Trial N Engl J Med, Volume 361(8):756-765, August 20, 2009 87 Incidence of New Vertebral, Nonvertebral, and Hip Fractures Cummings SR et al. N Engl J Med 2009;361:756-765 Percent Changes in Bone Mineral Density and Biochemical Markers of Bone Turnover Cummings SR et al. N Engl J Med 2009;361:756-765 89 Annual incidence of common diseases Significance of Osteoporosis in Women 2,051,0001 2,000,000 297,000 hip 1,500,000 397,000 wrist 675,000 other sites 1,000,000 135,000 pelvic 500,000 547,000 vertebral 0 Osteoporotic Fractures 425,0002 370,0002 182,4603 Stroke Heart Attack fracture incidence in women all ages estimate new & recurrent MI ages 35+ 2Annual estimate new & recurrent stroke in women all ages 32008 new cases in situ & invasive breast cancer all ages Breast Cancer 1Annual 2Annual 1 Burge, et al. JBMR. 2007. 465-75. American Heart Association. Heart Disease and Stroke Statistics – 2009 Update. 2009. 3 American Cancer Society. Surveillance Research. 2008. © 2008. National Osteoporosis Foundation. All rights reserved. www.nof.org “We enter the world through the brim of the pelvis, and frequently exit by the neck of the femur” C.A. Newhall, MD